Ubs Group Ag Cyclacel Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.52 - $0.76 $88 - $129	171 New	171 $0
Q3 2022 Nov 10, 2022	BUY	$1.23 - $21.9 $270 - $4,818	220 Added 10.47%	2,322 $3,000
Q2 2022 Aug 10, 2022	SELL	$6.1 - $7.15 $14,774 - $17,317	-2,422 Reduced 53.54%	2,102 $2,000
Q1 2022 May 16, 2022	BUY	$5.93 - $7.6 $18,383 - $23,560	3,100 Added 217.7%	4,524 $14,000
Q4 2021 Feb 14, 2022	BUY	$6.04 - $8.03 $8,600 - $11,434	1,424 New	1,424 $6,000
Q3 2021 Nov 15, 2021	SELL	$8.02 - $11.0 $577 - $792	-72 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$7.59 - $10.48 $17,305 - $23,894	-2,280 Reduced 96.94%	72 $0
Q1 2021 May 12, 2021	BUY	$6.86 - $9.24 $16,121 - $21,714	2,350 Added 117500.0%	2,352 $17,000
Q4 2020 Feb 11, 2021	SELL	$5.0 - $7.5 $14,960 - $22,440	-2,992 Reduced 99.93%	2 $0
Q3 2020 Nov 12, 2020	BUY	$4.81 - $6.49 $14,391 - $19,418	2,992 Added 149600.0%	2,994 $11,000
Q2 2020 Jul 31, 2020	BUY	$5.2 - $7.75 $10 - $15	2 New	2 $0

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.51M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.